Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 59

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Pneumonia+1

Not recruiting

A study testing trimodulin in hospitalized adult patients with community-acquired pneumonia including COVID-19 pneumonia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

Breast cancer+3

Not recruiting

Study of romiplostim for treating low platelet counts caused by chemotherapy in adults with non-small cell lung cancer, ovarian cancer, or breast cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Amgen Inc.

Chronic obstructive pulmonary disease

Not recruiting

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Pulmonary arterial hypertension

Not recruiting

A Study of PF-07868489 Safety and Effectiveness in Adults with Pulmonary Arterial Hypertension Who Participated in a Previous PF-07868489 Trial

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:PF-07868489
  • Sponsor:Pfizer Inc.

Conjunctivitis allergic+1

Not recruiting

Testing sublingual immunotherapy with dermatophagoides pteronyssinus extract for adults with moderate to severe house dust mite allergy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dermatophagoides Pteronyssinus Extract
  • Sponsor:ROXALL Medizin GmbH

Chronic obstructive pulmonary disease

Not recruiting

A Study of Inhaled Fexlamose for Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE
  • Sponsor:Aer Therapeutics Inc.

Pulmonary arterial hypertension

Not recruiting

Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Chronic obstructive pulmonary disease

Not recruiting

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

COVID-19

Not recruiting

A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:Gentofte Hospital

Influenza

Not recruiting

A Study to Test the Safety and Body's Response to TETRALITE Influenza Vaccine Compared to Vaxigrip Tetra Vaccine in Healthy Adults Aged 18 to 50 Years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:A/Victoria/2570/2019 (H1N1)Pdm09-Like Strain (A/Victoria/2570/2019, Ivr-215)
  • Sponsor:LiteVax B.V.

COVID-19

Not recruiting

A study to test the safety and immune response of PHH-1V111 vaccine against COVID-19 variants in adults

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years · Healthy volunteers
  • Sponsor:Hipra Scientific S.L.

Small cell lung cancer extensive stage+2

Not recruiting

Testing Tarlatamab in Patients with Advanced Small-Cell Lung Cancer Who Have Poor Physical Condition

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tarlatamab
  • Sponsor:AIO-Studien gGmbH

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.